Newswise — June 30, 2020 – Using an in-home portable air cleaner (PAC) can significantly reduce exposure to fine-particle air pollutants – a major risk factor for cardiovascular events in people with pre-existing heart disease, reports a pilot study in the July issue of Journal of Cardiopulmonary Rehabilitation and Prevention. The journal is published in the Lippincott portfolio by Wolters Kluwer.

“We show here for the first time that providing cardiac patients with PAC for use in their homes results in approximately a 40 percent reduction in personal-level exposure to PM2.5 air pollution,” according to the new research by Robert L. Bard, MS, of Michigan Medicine, Ann Arbor, and colleagues. They plan further studies to see if the reducing particulate exposure with PACs leads to reductions in cardiovascular events.

In-Home PACs Reduce Particulate Exposure, Can They Reduce Cardiovascular Events?

The Cardiac Rehabilitation Air Filter Trial (CRAFT) pilot study included 20 patients, average 71 years, undergoing cardiac rehabilitation at the authors’ medical center. Each patient received two PACs to use at home, running continuously: one in their bedroom and one in their main living space.

For the first five days, patients were randomly assigned to use their PAC in active mode, using a high-efficiency particulate air (HEPA) filter; or in sham mode, with no HEPA filter installed. For a subsequent five-day period, patients were crossed over to the other PAC mode. The study was “double-blind” – patients and researchers were both unaware of the order of the two modes.

After four days on each mode, patients were given a portable monitor to measure their personal exposure to fine-particle pollutants: particles or droplets measuring 2.5 microns in width. (A micron, or micrometer, is one-millionth of a meter.) Exposure to PM2.5 is a major risk factor for myocardial infarction, sudden death, and other events throughout the population, but especially in patients with cardiac disease.

In 18 patients who completed the study, exposure to fine-particle pollutants was significantly lower with the PAC in active mode. Compared to the sham period, active in-home PAC use reduced personal PM2.5 exposure by about 44 percent.

The improvement remained significant on analysis excluding a few patients with very high short-term PM2.5 values, possibly related to secondhand smoke or cooking. Use of active PAC with a HEPA filter reduced personal PM2.5 exposure for all but two of the 18 patients.

The results were similar to a previous study evaluating PAC use in a senior facility. The researchers also note that the reductions in PM2.5 exposure were achieved in a region (southeast Michigan) with good air quality; in more-polluted areas, even greater reductions might be achieved. The PAC devices are relatively inexpensive: retail cost of about $120 each.

“These pilot study findings are important because they validate the effectiveness of PAC in a real-world clinical setting and represent a critical next step required to rationalize and design large scale outcome trials,” Mr. Bard and coauthors write. By conservative estimates, the reported PM2.5 reductions might lower the cardiovascular event rate by five percent in the general population, and by up to 20 percent in high-risk cardiac patients.

The results support moving forward with the full-scale CRAFT study, which aims to show that PAC use can improve risk markers such as blood pressure or blood vessel (endothelial) function. The researchers conclude: “Such data are required to design future outcome trials which are urgently needed to help inform on how to protect the global public health from the threats posed by air pollution.”

Click here to read “Reduced Fine Particulate Matter Air Pollution Exposures Using In-Home Portable Air Cleaners.”

DOI: 10.1097/HCR.0000000000000516

###

About Journal of Cardiopulmonary Rehabilitation and Prevention

Journal of Cardiopulmonary Rehabilitation and Prevention was the first, and remains the only, professional journal dedicated to improving multidisciplinary clinical practice and expanding research evidence specific to both cardiovascular and pulmonary rehabilitation.  This includes exercise testing and prescription, behavioral medicine, and cardiopulmonary risk factor management.  In 2007, JCRP expanded its scope to include primary prevention of cardiovascular and pulmonary diseases.  JCRP publishes scientific and clinical peer-reviewed Original Investigations, Reviews, and Brief or Case Reports focused on the causes, prevention, and treatment of individuals with cardiovascular or pulmonary diseases in both a print and online-only format. Editorial features include Editorials, Invited Commentaries, Literature Updates, and Clinically-relevant Topical Updates.

Official Journal of the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on TwitterFacebookLinkedIn, and YouTube.

SEE ORIGINAL STUDY